Find information on thousands of medical conditions and prescription drugs.

Ovarian cancer

Ovarian cancer is a malignant ovarian neoplasm (an abnormal growth located on the ovaries). more...

Home
Diseases
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
Obesity
Obsessive-compulsive...
Occipital horn syndrome
OCD
Ochronosis
Oculocutaneous albinism,...
Oculopharyngeal muscular...
Odontophobia
Odynophobia
Oikophobia
Olfactophobia
Olivopontocerebellar atrophy
Omenn syndrome
Onchocerciasis
Oncocytoma
Ondine's curse
Opportunistic infections
Oppositional defiant...
Optic atrophy
Optic neuritis
Oral leukoplakia
Ornithosis
Orthostatic intolerance
Osgood-Schlatter disease
Osteitis deformans
Osteoarthritis
Osteochondritis
Osteochondritis dissecans
Osteochondroma
Osteogenesis Imperfecta
Osteomalacia
Osteomyelitis
Osteopetrosis, (generic...
Osteoporosis
Osteosclerosis
Otosclerosis
Otospondylomegaepiphyseal...
Ovarian cancer
P
Q
R
S
T
U
V
W
X
Y
Z
Medicines

Causes

Ovarian cancer is the fourth leading cause of cancer death in women, the leading cause of death from gynecologic malignancies and the second most commonly diagnosed gynecologic malignancy . It is idiopathic, meaning that the exact cause is unknown. The disease is more common in industrialized nations, with the exception of Japan. In the United States, females have a 1.4 % to 2.5 % (1 out of 40-60 women) lifelong chance of developing ovarian cancer.

Older women are at highest risk. More than half of the deaths from ovarian cancer occur in women between 55 and 74 years of age and approximately one quarter of ovarian cancer deaths occur in women between 35 and 54 years of age.

The risk for developing ovarian cancer appears to be affected by several factors. The more children a woman has, the lower her risk of ovarian cancer. Early age at first pregnancy, older ages of final pregnancy, and the use of some oral contraceptive pills have also been shown to have a protective effect. Ovarian cancer is reduced in women after tubal ligation.

The link to the use of fertility medication has been controversial. An analysis in 1991 raised the possibility that use of drugs tation may increase the risk for ovarian cancer. Several cohort studies and case-control studies have been conducted since then without providing conclusive evidence for such a link with the possible exception that prolonged use (> 1 year) of clomiphene citrate should be avoided.1 It will remain a complex topic to study as the infertile population differs in parity from the "normal" population.

There is good evidence that in some women genetic factors are important. Carriers of certain mutations of the BRCA1 or the BRCA2 gene (especially Ashkenazi Jewish women) are at a higher risk of both breast cancer and ovarian cancer, often at an earlier age than the general population. Patients with a personal history of breast cancer, or a family history of breast and/or ovarian cancer, may have an elevated risk. A strong family history of uterine cancer, colon cancer, or other gastrointestinal cancers may indicate the presence of a syndrome known as hereditary non-polyposis colon cancer (HNPCC), which confers a higher risk for developing ovarian cancer. Patients with strong genetic risk for ovarian cancer may consider the use of prophylactic oophorectomy after completion of child-bearing.

Other factors that have been investigated, such as talc use, asbestos exposure, high dietary fat content, and childhood mumps infection, are controversial and have not been definitively proven.

A study funded by American Cancer Society conducted at the H. Lee Moffitt Cancer Center of the University of South Florida has found a correlation between high levels of lysophospholipids (a type of fatty acid) with ovarian cancer patients and low levels of lysophospholipids with healthy women. This potential biomarker can be detected by a simple blood test. The blood test was 93 % accurate as predictor of ovarian cancer with less than 4 % false positives of the 117 women studied. Other indicators of ovarian cancer could be used to increase accuracy to 100 %. 2

Read more at Wikipedia.org


[List your site here Free!]


Symptoms of ovarian cancer
From American Family Physician, 3/15/05 by Caroline Wellbery

Although ovarian cancer has been thought to be asymptomatic until the late stages of the disease, recent studies have indicated that women with ovarian cancer reported symptoms before diagnosis, and these symptoms are similar for late and early disease stages. The most common complaints reported before diagnosis have included abdominal, gastrointestinal tract, pain, constitutional, urinary, and pelvic symtoms. Given that five-year survival for ovarian cancer is much higher with early diagnosis, a reliable set of symptoms to look for might facilitate early detection. Goff and colleagues performed a study of primary care patients to determine whether the frequency, severity, and duration of symptoms were more pronounced in women with ovarian cancer than in those seen for routine problems.

The authors surveyed women visiting two primary care sites regarding the severity, frequency, and duration of 20 symptoms associated with ovarian cancer. The same survey was given to women presenting at a specialty clinic for removal of an ovarian or pelvic mass.

Of the 1,709 patients who completed the survey, 25 percent were presenting for a general checkup, 13 percent were there for a mammogram, and 62 percent were being seen for specific problems. Of these women, 95 percent had at least one of the 20 listed symptoms in the previous year, with back pain reported most commonly (60 percent), then fatigue (52 percent), indigestion (37 percent), urinary tract symptoms (35 percent), constipation (33 percent), and abdominal pain (28 percent). Many of the symptoms recurred at least monthly in 72 percent of the women. Symptoms were most common in women with diabetes, thyroid disease, and irritable bowel syndrome (IBS). Postmenopausal women had fewer symptoms overall than premenopausal women. As age increased, all symptoms were less common except for urinary tract symptoms.

Of the 128 women with a pelvic mass, 84 had benign masses and 44 had malignancies, 11 with early stage disease and 33 with advanced disease. Women with malignancies had a higher median number of symptoms and recurring symptoms than the clinic patients, with 36 percent having had symptoms for two months or less, 24 percent having symptoms for two to three months, and 14 percent having symptoms longer than one year. When comparing women who had malignancy with women who had IBS (and, therefore, had high numbers of symptoms), a significantly higher percentage of women with malignancy had pelvic pain (41 versus 25 percent), bloating (70 versus 49 percent), increased abdominal size (64 versus 32 percent), and urinary tract symptoms (55 versus 33 percent). Women with ovarian cancer were significantly more likely than the clinic group to have pelvic pain, abdominal pain, difficulty eating, bloating, increased abdominal size, and urinary urgency.

In comparing groups of symptoms, 43 percent of women with ovarian cancer had the combination of bloating, abdominal pain, and urinary tract symptoms, whereas 10 percent of women with benign masses, 13 percent of women with IBS, and 8 percent of clinic women had this combination. Symptoms were more severe and more frequent in women with ovarian cancer or IBS than in clinic patients. Symptoms typically were continuous in women with malignancies, compared with occasional and intermittent symptoms in clinic patients. Women with benign masses also often had daily symptoms, which overlapped with the symptoms experienced by women with ovarian cancer, but included constipation. Finally, women with ovarian cancer had a much shorter duration of symptoms at a median of six months or less compared with 12 to 24 months in clinic patients and those with IBS.

No effective screening test exists for ovarian cancer. The symptoms most commonly reported in patients with ovarian cancer include bloating, increased abdominal size, abdominal or pelvic pain, and urinary tract symptoms, although these also are common in women with benign masses. Symptoms tend to be more severe, more frequent, and of shorter duration in women with malignant masses than in women with benign masses. Women with ovarian cancer also are more likely to present with a combination of symptoms.

The authors conclude that this study provides more evidence that ovarian cancer is not an asymptomatic disease. Symptoms that are more severe, more frequent, and of recent onset are more likely to be associated with ovarian masses.

Goff BA, et al. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA June 9, 2004;291:2705-12.

COPYRIGHT 2005 American Academy of Family Physicians
COPYRIGHT 2005 Gale Group

Return to Ovarian cancer
Home Contact Resources Exchange Links ebay